ArticleHepatology (Baltimore, Md.)2017
Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements.
Article in Hepatology (Baltimore, Md.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 4 syntheses or guidelines pooled it, 141 citations in OpenAlex.
- Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update.Hepatology international · 2024Guideline
- [Chinese guideline for diagnosis and management of drug-induced liver injury (2023 version)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023Guideline
- Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management.European journal of gastroenterology & hepatology · 2021Pooled it
- Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease.Alimentary pharmacology & therapeutics · 2020Guideline
- Eosinophilic cholecystitis associated with vanishing bile duct syndrome: a rare case report of drug-induced hepatobiliary injury.International journal of surgery case reports · 2026Article
- The contemporary epidemiology, causes, and management of drug-induced liver injury.Hepatology communications · 2026Review
- [A case of acetaminophen-induced cholestatic liver injury accompanying severe hypercholesterolemia in children].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Article
- Do drugs with biliary toxicity cause cholangiocarcinoma?bioRxiv : the preprint server for biology · 2026Article
- Antiseizure Treatments and Liver Injury: Expect (and Prevent) the Unexpected.Epilepsy currents · 2026Review
- Cefadroxil-associated cholestatic liver injury presenting as vanishing bile duct syndrome: a case report.Frontiers in medicine · 2026Article
- Vanished Without a Trace: A Middle-Aged Man With Vanishing Bile Duct Syndrome-A Case Report.Case reports in gastrointestinal medicine · 2026Article
- Oxymetholone-Associated Cholestatic Drug-Induced Liver Injury With Profound Hyperbilirubinaemia: A Longitudinal Case Report.Case reports in hepatology · 2026Article
- Lenalidomide-Associated Liver Injury With Features of Vanishing Bile Duct Syndrome in Multiple Myeloma.Cureus · 2025Article
- Drug-induced liver injury. Part II: Late complications and hepatotoxicity monitoring.Clinical and experimental hepatology · 2025Review
- Drug-Induced Liver Injury in Patients With Chronic Liver Disease.Liver international : official journal of the International Association for the Study of the Liver · 2025Review
- Role of liver biopsy in the management of idiosyncratic DILI.Liver international : official journal of the International Association for the Study of the Liver · 2025Review
- Drug-induced liver injury: Diagnosis, management and the role of liver transplantation.Hepatology forum · 2025Review
- A Case Report of Vanishing Bile Duct Syndrome Resulting From Thyroid Storm-Related Liver Injury and Postsurgical Biliary Tree Injury Overlap.Case reports in hepatology · 2025Article
- Acquired ductopenia: an insight into imaging findings.Abdominal radiology (New York) · 2025Review
- Clinical characteristics and HLA associations of azithromycin-induced liver injury.Alimentary pharmacology & therapeutics · 2024Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
11 authors at 9 institutions in 1 country.
Funding
Abstract
Bile duct loss during the course of drug-induced liver injury is uncommon, but can be an indication of vanishing bile duct syndrome (VBDS). In this work, we assess the frequency, causes, clinical features, and outcomes of cases of drug-induced liver injury with histologically proven bile duct loss. All cases of drug-induced liver injury enrolled into a prospective database over a 10-year period that had undergone liver biopsies (n = 363) were scored for the presence of bile duct loss and assessed for clinical and laboratory features, causes, and outcomes. Twenty-six of the 363 patients (7%) with drug-, herbal-, or dietary-supplement-associated liver injury had bile duct loss on liver biopsy, which was moderate to severe (<50% of portal areas with bile ducts) in 14 and mild (50%-75%) in 12. The presenting clinical features of the 26 cases varied, but the most common clinical pattern was a severe cholestatic hepatitis. The implicated agents included amoxicillin/clavulanate (n = 3), temozolomide (n = 3), various herbal products (n = 3), azithromycin (n = 2), and 15 other medications or dietary supplements. Compared to those without, those with bile duct loss were more likely to develop chronic liver injury (94% vs. 47%), which was usually cholestatic and sometimes severe. Five patients died and 2 others underwent liver transplantation for progressive cholestasis despite treatment with corticosteroids and ursodiol. The most predictive factor of poor outcome was the degree of bile duct loss on liver biopsy.
conclusionBile duct loss during acute cholestatic hepatitis is an ominous early indicator of possible VBDS, for which at present there are no known means of prevention or therapy. (Hepatology 2017;65:1267-1277).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.